Icon

CABOMETYX (nda208692)- (EQ 20MG BASE,EQ 40MG BASE,EQ 60MG BASE)

CABOZANTINIB S-MALATE EXELIXIS INC
EQ 20MG BASE,EQ 40MG BASE,EQ 60MG BASE
Yes No
2037-Apr-17 2017-Nov-29
None 2019-Apr-25
None No
CABOMETYX is a kinase inhibitor indicated for the treatment of • Patients with advanced renal cell carcinoma (RCC) • Patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab • Patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib • Adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
1 0 0
Total Other Developers 16
Drugs with Suitability No
EQ 20MG BASE ** ** - - -
EQ 40MG BASE ** ** - - -
EQ 60MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.